TriangleFluorouracil (NCT04205968)
Fluorouracil trial for Metastatic Small Intestinal Adenocarcinoma (NCT04205968). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
This trial is for adults with unresectable or metastatic small-bowel adenocarcinoma after progression on fluoropyrimidine, oxaliplatin, or both. Ampullary cancers and known MSI-high or mismatch-repair-deficient tumors are excluded.
The idea: compare ramucirumab plus paclitaxel with FOLFIRI chemotherapy. Ramucirumab blocks VEGFR-2 blood-vessel signaling; chemotherapy disrupts cancer-cell growth. Randomized groups receive intravenous treatment in 28-day cycles. Prior irinotecan, taxane or ramucirumab treatment for this cancer is excluded.
This phase 2 study plans 94 patients. Michael Overman leads the SWOG Cancer Research Network study, with 399 recruiting US sites. Researchers compare progression-free survival.
Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.